ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: It is possible that the reduced expression of miR-564 leads to an enhanced expression of E2F3 which assists in the oncogenic activity of BCR-ABL and the growth advantage seen in CML-blast crisis cells.